索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王洁 周鹏.CD40-肿瘤坏死因子受体相关因子抑制剂在动脉粥样硬化治疗中的研究进展[J].国际心血管病杂志,2020,01:1-4.
点击复制

CD40-肿瘤坏死因子受体相关因子抑制剂在动脉粥样硬化治疗中的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2020年01期
页码:
1-4
栏目:
综述
出版日期:
2020-01-14

文章信息/Info

Title:
-
作者:
王洁 周鹏
610500成都医学院第一附属医院心内科
Author(s):
-
关键词:
CD40;  动脉粥样硬化;  巨噬细胞;  血小板;  免疫治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2020.01.001
文献标识码:
-
摘要:
CD40-CD40配体(CD40L)信号通路与动脉粥样硬化相关,在动脉粥样硬化起始、发展和并发症中起重要作用。CD40/CD40L是一对互补的跨膜糖蛋白,广泛表达于免疫细胞、内皮细胞、血小板、平滑肌细胞等,参与免疫、炎性反应、血栓形成等多种病理生理过程。动脉粥样硬化启动CD40的表达,激活下游信号通路,上调炎性反应和血栓形成相关基因的表达,阻断该信号通路是抗动脉粥样硬化的策略之一。
Abstract:
-

参考文献/References

[ 1 ]Khera AV, Demler OV, Adelman SJ, et al. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events:an analysis from the Jupiter trial(justification for the use of statins in prevention:an intervention trial evaluating rosuvastatin)[J]. Circulation, 2017, 135(25):2494-2504.
[ 2 ]Lobatto ME, Calcagno C, Millon A, et al. Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging[J]. ACS Nano, 2015, 9(2):1837-1847.
[ 3 ]Wolf D, Ley K. Immunity and inflammation in atherosclerosis[J]. Herz, 2019, 44(2):107-120.
[ 4 ]Lutgens E, Atzler D, Döring Y, et al. Immunotherapy for cardiovascular disease[J]. Eur Heart J, 2019, 40(48):3937-3946.
[ 5 ]Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12):1119-1131.
[ 6 ]Schönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice[J]. Proc Natl Acad Sci U S A, 2000, 97(13):7458-7463.
[ 7 ]Lutgen E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype[J]. Proc Natl Acad Sci U S A, 2000, 97(13):7464-7469.
[ 8 ]Hueso M, De Ramon L, Navarro E, et al. Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis[J]. Atherosclerosis, 2016, 255:80-89.
[ 9 ]Perper SJ, Westmoreland SV, Karman J, et al. Treatment with a CD40 antagonist antibodyreverses severe proteinuria and loss of saliva production and restores glomerular morphology in murine systemic lupus erythematosus[J]. J Immunol, 2019, 203(1):58-75.
[10]Furman RR, Forero-Torres A, Shustov A, et al. A phase Ⅰ study of dacetuzumab(SGN-40,a humanized anti-CD40 monoclonal antibody)in patients with chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2010, 51(2):228-235.
[11]Advani R, Forero-Torres A, Furman RR, et al. Phase Ⅰ study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma[J]. J Clin Oncol, 2009, 27(26):4371-4377.
[12]Jansen MF, Hollander MR, Van Royen N, et al. CD40 in coronary artery disease: a matter of macrophages[J]. Basic Res Cardiol, 2016, 111(4):38.
[13]Ma B, Yang Y, Li Z, et al. Modular bioinformatics analysis demonstrates that a Toll-like receptor signaling pathway is involved in the regulation of macrophage polarization[J]. Mol Med Rep, 2018, 18(5):4313-4320.
[14]Honold L, Nahrendorf M. Resident and monocyte-derived macrophages in cardiovascular disease[J]. Circ Res, 2018, 122(1):113-127.
[15]Lim GB. Nanoimmunotherapy targeting CD40-TRAF6 signalling to reduce atherosclerosis[J]. Nat Rev Cardiol, 2018, 15(6):317.
[16]Missiou A, Köstlin N, Varo N, et al. Tumor necrosis factor receptor-associated factor 1(TRAF1)deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall[J]. Circulation, 2010, 121(18):2033-2044.
[17]Missiou A, Rudolf P, Stachon P, et al. TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation[J]. Circ Res, 2010, 107(6):757-766.
[18]Seibold K, Ehrenschwender M. P62 regulates CD40-mediated NF-κB activation in macrophages through interaction with TRAF6[J]. Biochem Biophys Res Commun, 2015, 464(1):330-335.
[19]Chen J, Song Y, Bojadzic D, et al. Small-molecule inhibitors of the CD40-CD40L costimulatory protein-protein interaction[J]. J Med Chem, 2017, 60(21):8906-8922.
[20]Zarzycka B, Seijkens T, Nabuurs SB, et al. Discovery of small molecule CD40-TRAF6 inhibitors[J]. J Chem Inf Model, 2015, 55(2):294-307.
[21]Chatzigeorgiou A, Seijkens T, Zarzycka B, et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance[J]. Proc Natl Acad Sci U S A, 2014, 111(7):2686-2691.
[22]Seijkens T, Van Tiel CM, Kusters P, et al. Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis[J]. J Am Coll Cardiol, 2018, 71(5):527-542.
[23]Van Den Berg SM, Seijkens TT, Kusters PJ, et al. Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice[J]. Int J Obes(Lond), 2015, 39(5):782-790.
[24]Duivenvoorden R, Tang J, Cormode DP, et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation[J]. Nat Commun, 2014, 5:3065.
[25]Lameijer M, Binderup T, van Leent MMT, et al. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates[J]. Nat Biomed Eng, 2018, 2(5):279-292.
[26]Kojok K, Akoum SE, Mohsen M, et al. CD40L priming of platelets via NF-κB activation is CD40-and TAK1-dependent[J]. J Am Heart Assoc, 2018, 7(23):e03677.
[27]Jin R, Xiao AY, Song Z, et al. Platelet CD40 mediates leukocyte recruitment and neointima formation after arterial denudation injury in atherosclerosis-prone mice[J]. Am J Pathol, 2018, 188(1):252-263.
[28]Simic D, Bogdan N, Teng F, et al. Blocking α5β1 integrin attenuates sCD40L-mediated platelet activation[J]. Clin Appl Thromb Hemost, 2017, 23(6):607-614.
[29]Rosetti F, Mayadas TN. The many faces of Mac-1 in autoimmune disease[J]. Immunol Rev, 2016, 269(1):175-193.
[30]Wolf D, Hohmann JD, Wiedemann A, et al. Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis-but does not affect immunity and thrombosis in mice[J]. Circ Res, 2011, 109(11):1269-1279.
[31]Gerdes N, Seijkens T, Lievens D, et al. Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes[J]. Arterioscler Thromb Vasc Biol, 2016, 36(3):482-490.
[32]Tang J, Baxter S, Menon A, et al. Immune cell screening of a nanoparticle library improves atherosclerosis therapy[J]. Proc Natl Acad Sci U S A, 2016, 113(44):E6731-E6740.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81641058); 四川省科技厅项目(2015JY0275); 北京力生心血管健康基金项目(LHJJJ20157620)
作者单位:610500成都医学院第一附属医院心内科
通信作者:周鹏,E-mail:ap216g@163.com
更新日期/Last Update: 2020-01-15